Discovery of Direct Growth Inhibition of Various Types of Cancer Cells by Fusarochromanone

Description:

Reference #: 00337

The University of South Carolina is offering sub-licensing opportunities for a compound that shows promise for the treatment of cancer, arthritis, and other angiogenic diseases. The compound strongly inhibits tumor growth and is also effective in inhibiting angiogenesis. This unique combination of anticancer activity and anti-angiogenic activity makes this compound attractive for clinical development.

Potential Applications:

This invention offers promise for the treatment of cancer and angiogenic diseases, including arthritis.

Advantages and Benefits:

  • Particularly attractive for clinical development because it both has anti-angiogenic properties and is highly inhibitory to a variety of cancer cell types

  • Directly toxic toward many cancer cell lines

  • Inhibits angiogenesis by inhibiting growth of human microvascular endothelial cells

  • Oral bioavailability—nearly equal in potency to intraperitoneal injection

  • Simple structure and favorable pharmacokinetics

  • Low toxicity in vivo, as well as in proliferation of normal, non-vascular cell lines

  • Optimized purification process isolates the highly pure compound from source material

Problem:

Angiogenis is the development of new blood vessels from existing capillaries. While the process normally develops healthy new blood vessels, it can be a factor in a number of human diseases, including the growth and metastasis of tumors and arthritis. In some forms of arthritis, new capillaries form in the joint, leading to its gradual destruction. Solid tumors also must stimulate the formation of new blood vessels in order to obtain the nutrients and oxygen that are necessary for their growth, and thus, angiogenesis can provide a route by which the tumors can metastasize to distant sites. Therefore, development of biologically active agents that inhibit angiogenesis is highly desirable because of their potential in providing effective treatment for cancer, arthritis, and other angiogenic diseases.

Invention Description:

The invention provides a treatment for angiogenic diseases in humans and animals. It is a small molecular weight, orally available compound that strongly inhibits tumor growth by acting in two ways. The compound shows potent anti-cancer activity against a variety of human tumor cells, while maintaining low toxicity to normal cells. The compound is also effective in inhibiting angiogenesis, which makes it effective in helping to stop the spread of tumors. This unique combination of anti-cancer activity and anti-angiogenic activity makes this compound attractive for clinical development. Furthermore, the compound has favorable pharmacokinetic properties with an in vivo half-life of over 12 hours. The purification process to isolate the highly pure compound from the natural source for preclinical studies has been optimized.

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Angiogenesis inhibitor for the treatment of cancer Utility United States 08/975,813 5,932,611 11/21/1997 8/3/1999 11/21/2017  
For Information, Contact:
Technology Commercialization
University of South Carolina
technology@sc.edu
Inventors:
Daotai Nie
Roy Wuthier
Licia Wu
Brian Genge
Keywords:
© 2018. All Rights Reserved. Powered by Inteum